MIDTERM DRUGS

Question 1

Bevacizumab

Answer 1

CLASSIFICATION: Monoclonal antibody

MECHANISM OF ACTION: Angiogenesis inhibition through Vascular Endothelial Growth Factor (VEGF) neutralisation

Question 2

Ipilimumab

Answer 2

CLASSIFICATION: Immune checkpoint inhibitor

MECHANISM OF ACTION: CTLA-4 blockade, fostering enhanced cytotoxic T-lymphocyte activity

Question 3

Trastuzumab

Answer 3

CLASSIFICATION: Monoclonal antibody

MECHANISM OF ACTION: HER2 receptor targeting, impeding proliferation of HER2-positive cancer cells

Question 4

Osimertinib

Answer 4

CLASSIFICATION: Tyrosine kinase inhibitor

MECHANISM OF ACTION: Selective inhibition of mutant forms of Epidermal Growth Factor Receptor (EGFR) in non-small cell lung cancer (NSCLC)

Question 5

Pembrolizumab

Answer 5

CLASSIFICATION: Immune checkpoint inhibitor

MECHANISM OF ACTION: PD-1 pathway blockade, facilitating immune response against neoplastic entities